Embecta CorpEMBC
▼ NegativeCapitalrelevance
Securities fraud lawsuit and missed guidance due to share loss and dividend cut
Impact on stocks 1
Health Care
Embecta CorpEmbecta Faces Securities Fraud Class Action Over Insulin Pen Issues
Regulation
A securities fraud class action lawsuit has been filed against Embecta Corp. and certain senior executives following a 57.8% stock drop on May 5, 2026. The complaint alleges that Embecta misled investors about the strength of its insulin pen needle product category, while in reality it faced significant competition and overall market softness. The stock decline occurred after the company announced disappointing second-quarter 2026 results that missed guidance due to share loss in its pen needle category, mostly from a single customer, and reduced its quarterly dividend from $0.15 to $0.01 per share. Investors have until August 17, 2026 to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.
Embecta CorpSecurities fraud lawsuit and missed guidance due to share loss and dividend cut